About Research at PCC

From discovery to application: prostate cancer research is forging a new frontier of hope
 

Prostate cancer is the most common cancer in Canadian men, with one in eight facing a diagnosis during his lifetime. Over the course of the past 20 years, however, deaths from prostate cancer have decreased by approximately 40 percent. This reduction is attributable to a number of advances in the areas of early detection, treatment, and equally as important, public education, awareness, and support of those living with the disease. Each of these advances has been made possible thanks to our most effective method of producing new, evidence-based understanding: research.

In much the same way as research has been the driving force behind progress made to date, it will continue to be the engine of new knowledge generation. This means developing ways of detecting the disease earlier and with more accuracy; personalizing treatments and reducing their side-effects; devising health systems and survivorship support programs that make care as accessible, holistic, and valuable as possible; and saving more lives.

To this end, Prostate Cancer Canada is helping lead the charge by investing heavily in Canada’s most promising studies and minds in the field of prostate cancer research. We ensure the most effective and efficient allocation of the funds we bring in through various means by employing a rigorous peer review process that seeks the guidance of experts from around the world to determine which projects to invest in to further reduce the burden of the disease.

In addition, we place a strong emphasis on supporting men and their circles of care throughout the prostate cancer journey. Given the high incidence of the disease and increasing survival rates, providing equal access to high quality educational and support resources and services is an imperative pillar of our mandate.
Without the support of generous Canadian individuals and organizations, none of this would be possible. On behalf of the one in eight men and their networks of love and support, we thank you for your support. We’re all in this together.

Donations in action

 



 

 

 





Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
BRCA2 gene implicated in rare but lethal prostate cancer

January 9, 2017 – TORONTO, ON – Canadian scientists have discovered a link between an inherited mutation in the BRCA2 gene and a deadly form of prostate cancer.
More

Scientists identify DNA signature linked to prostate cancer severity

January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature.
More

Thank You to our Canadian Mo Bros and Sistas!

TORONTO, December 1, 2016 - Prostate Cancer Canada congratulates the more than 500,000 Mo Bros and Mo Sistas worldwide who participated in this year's Movember campaign.
More


Click here for news archive